Suppr超能文献

镁、高海拔及急性高原病对大脑中动脉血流速度的影响。

Effect of magnesium, high altitude and acute mountain sickness on blood flow velocity in the middle cerebral artery.

作者信息

Lysakowski Christopher, Von Elm Erik, Dumont Lionel, Junod Jean-Daniel, Tassonyi Edömer, Kayser Bengt, Tramèr Martin R

机构信息

Neuroanaesthesia Unit, Division of Anaesthesiology, Department of Anaesthesiology, Pharmacology and Surgical Intensive Care, Geneva University Hospitals, Geneva, Switzerland.

出版信息

Clin Sci (Lond). 2004 Mar;106(3):279-85. doi: 10.1042/CS20030188.

Abstract

Cerebral blood flow is thought to increase at high altitude and in subjects suffering from acute mountain sickness (AMS); however, data from the literature are contentious. Blood flow velocity in the middle cerebral artery (MCAv) may be used as a proxy measure of cerebral blood flow. Using transcranial Doppler sonography, MCAv was measured during normo- and hyper-ventilation in subjects who participated in a trial that tested the effect of magnesium supplementation on the prevention of AMS. First, MCAv was recorded at 353 m (baseline). Subjects were then randomized to receive oral magnesium citrate and matching placebo. A second measurement was taken after a 24 +/- 2 h ascent from 1130 m to 4559 m (altitude I), and a third after a 20-24 h stay at 4559 m (altitude II). Using multivariate linear regression, an association was sought between MCAv and magnesium supplementation, subjects' age and gender, altitude itself, a temporary stay at altitude, and the presence of AMS (Lake Louise Score >6 with ataxia, nausea and/or headache). Subjects with AMS had additional Doppler recordings immediately before and after rescue medication (oxygen, dexamethasone and acetazolamide). Forty-seven subjects had measurements at baseline, 39 (21 receiving magnesium and 18 placebo) at altitude I and 26 (13 receiving magnesium and 13 placebo) at altitude II. During hyperventilation, MCAv decreased consistently (for each measurement, P<0.001). Magnesium significantly increased MCAv by 8.4 cm.s(-1) (95% confidence interval, 1.8-15), but did not prevent AMS. No other factors were associated with MCAv. Eleven subjects had severe AMS [median score (range), 11 (8-16)] and, after rescue medication, the median score decreased to 3 (range, 0-5; P=0.001), but MCAv remained unchanged (65 +/- 18 cm.s(-1) before compared with 67 +/- 16 cm.s(-1) after rescue medication; P=0.79). MCAv was increased in subjects who received magnesium, but was not affected by exposure to high altitude or by severe AMS.

摘要

人们认为,在高海拔地区以及患有急性高原病(AMS)的受试者中,脑血流量会增加;然而,文献数据存在争议。大脑中动脉血流速度(MCAv)可作为脑血流量的替代指标。本研究使用经颅多普勒超声,在参与一项测试补充镁对预防AMS效果试验的受试者进行正常通气和过度通气期间测量MCAv。首先,在海拔353米处(基线)记录MCAv。然后,受试者被随机分为两组,分别接受口服柠檬酸镁和匹配的安慰剂。在从1130米上升至4559米(海拔I)24±2小时后进行第二次测量,在4559米停留20 - 24小时后(海拔II)进行第三次测量。使用多元线性回归分析,研究MCAv与补充镁、受试者年龄和性别、海拔本身、在高海拔地区的短暂停留以及AMS的存在(路易斯湖评分>6,伴有共济失调、恶心和/或头痛)之间的关联。患有AMS的受试者在使用救援药物(氧气、地塞米松和乙酰唑胺)之前和之后立即进行额外的多普勒记录。47名受试者在基线时进行了测量,39名(21名接受镁,18名接受安慰剂)在海拔I时进行了测量,26名(13名接受镁,13名接受安慰剂)在海拔II时进行了测量。在过度通气期间,MCAv持续下降(每次测量,P<0.001)。镁使MCAv显著增加8.4厘米·秒⁻¹(95%置信区间,1.8 - 15),但并未预防AMS。没有其他因素与MCAv相关。11名受试者患有严重AMS [中位数评分(范围),11(8 - 16)],在使用救援药物后,中位数评分降至3(范围,0 - 5;P = 0.001),但MCAv保持不变(使用救援药物前为65±18厘米·秒⁻¹,使用后为67±16厘米·秒⁻¹;P = 0.79)。接受镁的受试者MCAv增加,但不受高海拔暴露或严重AMS的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验